AffiliationDepartment of Medical Oncology, Christie NHS Foundation Trust, Manchester M20 4BX, UK ; School of Cancer and Imaging Sciences, University of Manchester, Manchester M13 9PL, UK.
MetadataShow full item record
AbstractThe development of personalised therapy and mechanism-targeted agents in oncology mandates the identification of the patient populations most likely to benefit from therapy. This paper discusses the increasing evidence as to the heterogeneity of the group of diseases called colorectal cancer. Differences in the aetiology and epidemiology of proximal and distal cancers are reflected in different clinical behaviour, histopathology, and molecular characteristics of these tumours. This may impact response both to standard cytotoxic therapies and mechanism-targeted agents. This disease heterogeneity leads to challenges in the design of clinical trials to assess novel therapies in the treatment of "colorectal cancer."
CitationHow many diseases are colorectal cancer? 2012, 2012:564741 Gastroenterol Res Pract
JournalGastroenterology Research and Practice
- Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
- Authors: Chan KK, Glenny AM, Weldon JC, Furness S, Worthington HV, Wakeford H
- Issue date: 2015 Dec 1
- KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
- Authors: Health Quality Ontario.
- Issue date: 2010
- The Challenge of Developing New Therapies for Childhood Cancers.
- Authors: Balis FM
- Issue date: 1997
- Overview of resistance to systemic therapy in patients with breast cancer.
- Authors: Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN
- Issue date: 2007
- Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
- Authors: Colditz GA
- Issue date: 2010